ArticleCell2017
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 798 papers.
0numbers the graph read from it
0cells of the map it votes in
798citing papers in PubMed
50.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
798 citing papers in PubMed, 1,180 citations in OpenAlex.
- Trial
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- Inhibition of the lipocalin-2-phosphatidylserine axis restores natural killer cell immune surveillance.Cell reports. Medicine · 2026Article
- The development of single-cell lineage tracing technology and its application in immunotherapy.Molecular therapy. Advances · 2026Review
- A spatial immune scoring system based on the tumor microenvironment features improves prognostic stratification in lung adenocarcinoma.Translational oncology · 2026Article
- Effect of Tertiary Lymphoid Structures on Immune Cell Infiltration in the Tumor Microenvironment and Prognosis in Lung Adenocarcinoma.Cancer medicine · 2026Article
- Innovative immunotherapeutic strategies for thyroid cancer: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Monocarboxylate Transporter 2 (MCT2) Reduction Is Associated with Increased Lung Tumor Growth and Alterations in the Immune Microenvironment in a Subcutaneous Tumor Model.International journal of molecular sciences · 2026Article
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- Radiotherapy and immunotherapy in cancer treatment: mechanisms of clinical synergy.The Journal of clinical investigation · 2026Review
- scRNA-Seq in Gastric Cancer Reveals Macrophage-Derived C1q as a Diagnostic Marker.Cancer science · 2026Article
- Loss of NCCRP1 overcomes immune evasion in lung adenocarcinoma.Journal for immunotherapy of cancer · 2026Article
- Innate Immune Cells in Non-Small Cell Lung Cancer: Roles in Tumor Progression and Therapeutic Responses.Cancer innovation · 2026Review
- Spatiotemporal multi-omics reveals lineage, spatial and functional heterogeneity of tumor-associated macrophages and therapeutic vulnerabilities in the tumor microenvironment.NPJ precision oncology · 2026Review
- Integrated Transcriptomic Analysis ofInternational journal of molecular sciences · 2026Article
- Clonal lineage tracing of innate immune cells in human cancer.Cancer cell · 2026Article
- Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity.Med (New York, N.Y.) · 2026Article
- Reprogramming macrophages to treat liver diseases.Hepatology (Baltimore, Md.) · 2026Review
- Pan-cancer atlas of cellular architecture reveals a nearest-neighbour distance-associated biomechanical-immune axis involving CD4+ memory T cells.Clinical and translational medicine · 2026Article
- Tumor-distant pulmonary immune landscapes are associated with postoperative outcomes in non-small cell lung cancer.Translational lung cancer research · 2026Article
738 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
29 authors at 4 institutions in 2 countries.
Yonit LavinDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Soma KobayashiDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Andrew LeaderDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
El-Ad David AmirThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Naama ElefantDepartment of Immunology, Weizmann Institute, Rehovot 76100, Israel.
Camille BigenwaldDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Romain RemarkDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Robert SweeneyDepartment of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Christian D BeckerDivision of Pulmonology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Jacob H LevineComputational and Systems Biology Program, Sloan Kettering Institute, New York, NY 10065, USA.
Klaus MeinhofDivision of Pulmonology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Andrew ChowDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Seunghee Kim-ShulzeThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Andrea WolfDepartment of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Chiara MedagliaDepartment of Immunology, Weizmann Institute, Rehovot 76100, Israel.
Hanjie LiDepartment of Immunology, Weizmann Institute, Rehovot 76100, Israel.
Julie A RytlewskiAdaptive Biotechnologies Inc., Seattle, WA 98102, USA.
Ryan O EmersonAdaptive Biotechnologies Inc., Seattle, WA 98102, USA.
Alexander SolovyovDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Benjamin D GreenbaumDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Catherine SandersAdaptive Biotechnologies Inc., Seattle, WA 98102, USA.
Marissa VignaliAdaptive Biotechnologies Inc., Seattle, WA 98102, USA.
Mary Beth BeasleyDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Raja FloresDepartment of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Sacha GnjaticThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Dana Pe'erComputational and Systems Biology Program, Sloan Kettering Institute, New York, NY 10065, USA.
Adeeb RahmanThe Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Ido AmitDepartment of Immunology, Weizmann Institute, Rehovot 76100, Israel.
Miriam MeradDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; The Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: miriam.merad@mssm.edu.
Icahn School of Medicine at Mount Sinai · USAdaptive Biotechnologies (United States) · USWeizmann Institute of Science · ILKettering University · US
Funding
Viral Assays CoreU19AI128949 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Donna L. Farber, Peter Alan Sims · 2017 to 2026
$26.4MProject I: Immunity to Influenza in Primary Lung Epithelial CellsU19AI117873 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAYOT, FERNAND · 2015 to 2019
$8.6MERK control of Dendritic Cell Differentiation, Homeostasis and DiseaseR01CA154947 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CARL E ALLEN, MIRIAM MERAD · 2011 to 2026
$7.0MCELLULAR AND MOLECULAR FOUNDATIONS OF BIOMEDICAL SCIENCET32GM008798 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI PRYWES, RON M · 2001 to 2018
$6.3MSingle cell mapping of developmental trajectories underlying health and diseaseDP1HD084071 · NICHD · SLOAN-KETTERING INST CAN RESEARCH · PI PE'ER, DANA · 2014 to 2018
$4.2MNovel tools to maximize profiling of tissue and antigen specific immune dysregulation in allergy and inflammatory bowel disesaseU24AI118644 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BERIN, CECILIA, MERAD, MIRIAM · 2015 to 2020
$2.4MContribution of the cutaneous APC network to melanoma progression and therapy.R01CA173861 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MERAD, MIRIAM · 2013 to 2017
$2.1MHarnessing Csf-2 compartmentalized role on tissue resident phagocytes to uncouple anti-tumoral from pathological immunity induced by checkpoint inhibitorsR01CA190400 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MERAD, MIRIAM · 2015 to 2019
$1.9MIntegrative Cancer Genomics: Drivers, Pathways and DrugsR01CA164729 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI PE'ER, DANA · 2012 to 2016
$1.9MNCI NIH HHS R01 CA154947NCI NIH HHS R01 CA164729NCI NIH HHS R01 CA173861NCI NIH HHS R01 CA190400NIAID NIH HHS U19 AI117873NIAID NIH HHS U19 AI128949NIAID NIH HHS U24 AI118644NICHD NIH HHS DP1 HD084071NIGMS NIH HHS T32 GM008798
Abstract
To guide the design of immunotherapy strategies for patients with early stage lung tumors, we developed a multiscale immune profiling strategy to map the immune landscape of early lung adenocarcinoma lesions to search for tumor-driven immune changes. Utilizing a barcoding method that allows a simultaneous single-cell analysis of the tumor, non-involved lung, and blood cells, we provide a detailed immune cell atlas of early lung tumors. We show that stage I lung adenocarcinoma lesions already harbor significantly altered T cell and NK cell compartments. Moreover, we identified changes in tumor-infiltrating myeloid cell (TIM) subsets that likely compromise anti-tumor T cell immunity. Paired single-cell analyses thus offer valuable knowledge of tumor-driven immune changes, providing a powerful tool for the rational design of immune therapies. VIDEO ABSTRACT.
Indexed as
Immunity, InnateAdenocarcinomaAdenocarcinoma of LungDendritic CellsHumansKiller Cells, NaturalLung NeoplasmsMacrophagesSingle-Cell AnalysisT-LymphocytesTumor MicroenvironmentCD141+ DCCD1c+ DChuman non-small cell lung cancer (NSCLC)immune cell atlaslung adenocarcinomaNK CellT CellTIMTLStumor macrophage
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.